zbMATH — the first resource for mathematics

Joint model for left-censored longitudinal data, recurrent events and terminal event: predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000–05 trial. (English) Zbl 1390.62278
Summary: In oncology, the international WHO and RECIST criteria have allowed the standardization of tumor response evaluation in order to identify the time of disease progression. These semi-quantitative measurements are often used as endpoints in phase II and phase III trials to study the efficacy of new therapies. However, through categorization of the continuous tumor size, information can be lost and they can be challenged by recently developed methods of modeling biomarkers in a longitudinal way. Thus, it is of interest to compare the predictive ability of cancer progressions based on categorical criteria and quantitative measures of tumor size (left-censored due to detection limit problems) and/or appearance of new lesions on overall survival. We propose a joint model for a simultaneous analysis of three types of data: a longitudinal marker, recurrent events, and a terminal event. The model allows to determine in a randomized clinical trial on which particular component treatment acts mostly. A simulation study is performed and shows that the proposed trivariate model is appropriate for practical use. We propose statistical tools that evaluate predictive accuracy for joint models to compare our model to models based on categorical criteria and their components. We apply the model to a randomized phase III clinical trial of metastatic colorectal cancer, conducted by the Fédération Francophone de Cancérologie Digestive (FFCD 2000–05 trial), which assigned 410 patients to two therapeutic strategies with multiple successive chemotherapy regimens.

62P10 Applications of statistics to biology and medical sciences; meta analysis
62N01 Censored data models
62H12 Estimation in multivariate analysis
Full Text: DOI
[1] An, Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials, Clinical Cancer Research 17 pp 6592– (2011) · doi:10.1158/1078-0432.CCR-11-0822
[2] Claret, Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer, Journal of Clinical Oncology 31 pp 2110– (2013) · doi:10.1200/JCO.2012.45.0973
[3] Commenges, Choice of prognostic estimators in joint models by estimating differences of expected conditional Kullback-Leibler risks, Biometrics 68 pp 380– (2012) · Zbl 1251.62041 · doi:10.1111/j.1541-0420.2012.01753.x
[4] Ducreux, Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): An open-label, randomised, phase 3 trial, The Lancet Oncology 12 pp 1032– (2011) · doi:10.1016/S1470-2045(11)70199-1
[5] Efendi, A joint model for longitudinal continuous and time-to-event outcomes with direct marginal interpretation, Biometrical Journal 55 pp 572– (2013) · Zbl 1441.62335 · doi:10.1002/bimj.201200159
[6] Eisenhauer, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer 45 pp 228– (2009) · doi:10.1016/j.ejca.2008.10.026
[7] Elashoff, A joint model for longitudinal measurements and survival data in the presence of multiple failure types, Biometrics 64 pp 762– (2008) · Zbl 1170.62067 · doi:10.1111/j.1541-0420.2007.00952.x
[8] Genz, Fully symmetric interpolatory rules for multiple integrals over infinite regions with Gaussian weight, Journal of Computational and Applied Mathematics 71 pp 299– (1996) · Zbl 0856.65011 · doi:10.1016/0377-0427(95)00232-4
[9] Gerds, Consistent estimation of the expected Brier score in general survival models with right-censored event times, Biometrical Journal 48 pp 1029– (2006) · doi:10.1002/bimj.200610301
[10] Ibrahim, Bayesian methods for joint modeling of longitudinal and survival data with applications to cancer vaccine trials, Statistica Sinica 14 pp 863– (2004) · Zbl 1073.62100
[11] Jacqmin-Gadda, Analysis of left-censored longitudinal data with application to viral load in HIV infection, Biostatistics 1 pp 355– (2000) · Zbl 1096.62507 · doi:10.1093/biostatistics/1.4.355
[12] Karrison, Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non small-cell lung cancer, Journal of the National Cancer Institute 99 pp 1455– (2007) · doi:10.1093/jnci/djm158
[13] Liu, Joint analysis of correlated repeated measures and recurrent events processes in the presence of death, with application to a study on acquired immune deficiency syndrome, Journal of the Royal Statistical Society 58 pp 65– (2009) · doi:10.1111/j.1467-9876.2008.00641.x
[14] Liu, Analysis of longitudinal data in the presence of informative observational times and a dependent terminal event, with application to medical cost data, Biometrics 64 pp 950– (2008) · Zbl 1145.62388 · doi:10.1111/j.1541-0420.2007.00954.x
[15] Liu, Shared frailty models for recurrent events and a terminal event, Biometrics 60 pp 747– (2004) · Zbl 1274.62827 · doi:10.1111/j.0006-341X.2004.00225.x
[16] Lyles, Random regression models for human immunodeficiency virus ribonucleic acid data subject to left censoring and informative drop-outs, Journal of the Royal Statistical Society: Series C (Applied Statistics) 49 pp 485– (2000) · Zbl 0965.62097 · doi:10.1111/1467-9876.00207
[17] Marquardt, An algorithm for least-squares estimation of nonlinear parameters, SIAM Journal on Applied Mathematics 11 pp 431– (1963) · Zbl 0112.10505 · doi:10.1137/0111030
[18] Mauguen, Dynamic prediction of risk of death using history of cancer recurrences in joint frailty models, Statistics in Medicine 32 pp 5366– (2013) · doi:10.1002/sim.5980
[19] Molenberghs, A family of generalized linear models for repeated measures with normal and conjugate random effects, Statistical Science 25 pp 325– (2010) · Zbl 1329.62342 · doi:10.1214/10-STS328
[20] Proust-Lima, Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: A joint modeling approach, Biostatistics 10 pp 535– (2009) · doi:10.1093/biostatistics/kxp009
[21] Rizopoulos, Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data, Biometrics 67 pp 819– (2011) · Zbl 1226.62124 · doi:10.1111/j.1541-0420.2010.01546.x
[22] Rizopoulos, Fast fitting of joint models for longitudinal and event time data using a pseudo-adaptive Gaussian quadrature rule, Computational Statistics and Data Analysis 56 pp 491– (2012) · Zbl 1239.62122 · doi:10.1016/j.csda.2011.09.007
[23] Rondeau, Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events, Biometrics 8 pp 708– (2007) · Zbl 1267.62110
[24] Rondeau, frailtypack: An r package for the analysis of correlated survival data with frailty models using penalized likelihood estimation or parametrical estimation, Journal of Statistical Software 47 (2012) · doi:10.18637/jss.v047.i04
[25] Royston, Dichotomizing continuous predictors in multiple regression: A bad idea, Statistics in Medicine 25 pp 127– (2006) · doi:10.1002/sim.2331
[26] Schluchter, Methods for the analysis of informatively censored longitudinal data, Statistics in Medicine 11 pp 1861– (1992) · doi:10.1002/sim.4780111408
[27] Séne, Joint modeling of longitudinal and time-to-event data with application to the prediction of prostate cancer recurrence, Journal de la Société Française de Statistique 155 pp 134– (2013)
[28] WHO 1979 WHO Handbook for reporting results of cancer treatment
[29] Wulfsohn, A joint model for survival and longitudinal data measured with error, Biometrics 53 pp 330– (1997) · Zbl 0874.62140 · doi:10.2307/2533118
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. It attempts to reflect the references listed in the original paper as accurately as possible without claiming the completeness or perfect precision of the matching.